Cost-effectiveness analysis and efficient use of the pharmaceutical budget: The key role of clinical pharmacologists

British Journal of Clinical Pharmacology

Volumn 70, Issue 3, 2010, Pages 350-355

  Edlin, Richard ^a   Round, Jeff ^a   Hulme, Claire ^a   McCabe, Christopher ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Budget; Cost effectiveness; Efficiency; Opportunity costs

Indexed keywords

BUDGET; CLINICAL PHARMACOLOGIST; CLINICAL PHARMACOLOGY; CONCEPTUAL FRAMEWORK; COST BENEFIT ANALYSIS; HEALTH CARE; HEALTH CARE SYSTEM; HEALTH PRACTITIONER; HUMAN; NATIONAL HEALTH SERVICE; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; UNITED KINGDOM;

BUDGETS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG UTILIZATION; ECONOMICS, PHARMACEUTICAL; GREAT BRITAIN; HUMANS; PHARMACISTS; STATE MEDICINE;

EID: 77955733981     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03617.x     Document Type: Review

References (13)

1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford : Oxford University Press, 2005.
2. Brazier JE, Ratcliffe J, Tsuchiya A, Salomon J. Measuring and valuing health benefits for economic evaluation. Oxford : Oxford University Press, 2006.
3. Arnold D, Girling A, Stevens A, Liliford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. Br Med J 2009 339 : b2688.
4. Briggs AH, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford : Oxford University Press, 2006.
5. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005 187 : 106 108.
6. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001 10 : 779 787.
7. Culyer AJ, McCabe C, Briggs AH, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy 2007 12 : 56 28.
8. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008 26 : 733 744.
9. Martin S, Rice N, Smith PC. The link between health care spending and health outcomes for the new English Primary Care Trusts, CHE Research Paper 42; 2008. Centre for Health Economics, University of York.
10. Mitton C, Donaldson C. Twenty-five years of programme budgeting and marginal analysis in the health sector, 1974-1999. J Health Serv Res Policy 2001 6 : 239 248.
11. National Institute of Health and Clinical Excellence. Legal context of NICE guidance. Available at http://www.nice.org.uk/media/8BD/2B/Legal-context- nice-guidance.pdf (last accessed 1 August 2009).
12. General Medical Council. Guidance for Doctors: Management for Doctors. London : GMC, 2006.
13. Hébert PC, Stanbrook M. Indication creep: physician beware. Can Med Assoc J 2007 177 : 697.